Summary & Overview

Upper Limb and Toe Amputation for Circulatory System Disorders with CC: Inpatient Reimbursement Overview

DRG 256 addresses upper limb and toe amputations performed for circulatory system disorders when a Complication or Comorbidity is present, defining the clinical scope as ischemic or infection-related amputations with added clinical complexity. This grouping matters for inpatient reimbursement because it bundles payment to reflect higher expected resource use when a Complication or Comorbidity exists and hinges on precise documentation and coding.

Upper Limb and Toe Amputation for Circulatory System Disorders with CCDRG Upper Limb and Toe Amputation for Circulatory System Disorders with CCDRG 256Diagnosis-Related GroupInpatient ReimbursementMedicareVascular SurgeryAmputationWound CarePeripheral Vascular Disease

DRG 256 Overview

DRG 256 covers inpatient hospitalizations for upper limb and toe amputations performed for circulatory system disorders when a Complication or Comorbidity is present. It encompasses surgical removal of digits or extremities due to ischemia, infection, or other vascular insufficiency in patients with additional clinical complexity. This Diagnosis-Related Group matters for Medicare payment because it groups cases with similar resource needs and assigns a bundled payment that reflects the increased costs associated with added comorbidity. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus affect reimbursement.

National Payment Rates

Across payers the observed payment range spans approximately $370 up to $62K, with the widest spread between the minimum and maximum observed values across payers being about $62K. Benchmarks by payer (Cigna, Blue Cross Blue Shield, Aetna, Anthem) are shown in the table and chart below to illustrate payer-specific medians and quartiles. These visual comparisons highlight substantial variability across commercial plans.

Mean Rates by Payer — National — DRG 256

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates in Alaska for DRG 256 range from $26K to $41K across reported payers, with Cigna at the top end and Blue Cross Blue Shield and Anthem at the bottom. Cigna’s mean of $41K stands out as a meaningful deviation above national averages and medians. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna at a mean of $41K; lowest payer(s): Blue Cross Blue Shield and Anthem at a mean of $26K.
Alaska’s payer range spans from $26K to $41K, with Cigna materially above national means for several payers, indicating a notable upward deviation versus national medians.

Clinical Trials

Acute perioperative optimization trials: randomized or pragmatic studies testing protocols to reduce perioperative complications (e.g., infection, cardiovascular events, wound healing complications) in patients undergoing upper limb or toe amputation for ischemic or other circulatory system disorders. These studies enroll hospitalized adults with advanced peripheral arterial disease, critical limb ischemia, or diabetic foot ischemia who require amputation and compare specific perioperative bundles (such as antibiotic regimens, glycemic control strategies, hemodynamic monitoring thresholds, or limb perfusion optimization) versus usual care. Results are directly relevant to surgeons, hospitalists, and payers because improved perioperative management can reduce length of stay, readmissions, and high-cost complications that drive inpatient reimbursement under this DRG.
Comparative effectiveness research on amputation level and technique: observational cohort studies or randomized trials evaluating functional outcomes, stump healing, reoperation rates, and resource use between different amputation levels (toe vs transmetatarsal vs partial foot; forearm vs more proximal upper limb) and surgical techniques (flap design, bone management, closure methods) in patients with circulatory system-related tissue loss. These studies focus on patients stratified by vascular status, comorbidities such as diabetes and renal disease, and baseline mobility to determine which approaches maximize tissue viability and preserve function while minimizing complications. Findings inform surgeons and payers about which procedures provide the best balance of clinical benefit and cost-effectiveness for specific patient subgroups, influencing DRG-related utilization and post-acute care needs.
Post-discharge outcomes and care coordination studies: prospective cohort studies and intervention trials examining rehabilitation access, prosthetic fitting timelines, wound care follow-up, and secondary prevention (vascular risk modification) on long-term outcomes like mobility, quality of life, recurrent limb events, and readmissions in patients discharged after toe or upper limb amputation for circulatory disease. These investigations enroll patients transitioning from inpatient care to home or skilled nursing, testing care-management models, telehealth wound monitoring, or structured vascular clinics to reduce avoidable readmissions and recurrent ischemic events. Results are critical for payers and health systems because effective post-discharge strategies can lower downstream costs, influence bundled payment performance, and improve metrics that affect DRG reimbursement risk.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$15K	$74K	$12K	1.1K

Acute perioperative optimization trials: randomized or pragmatic studies testing protocols to reduce perioperative complications (e.g., infection, cardiovascular events, wound healing complications) in patients undergoing upper limb or toe amputation for ischemic or other circulatory system disorders. These studies enroll hospitalized adults with advanced peripheral arterial disease, critical limb ischemia, or diabetic foot ischemia who require amputation and compare specific perioperative bundles (such as antibiotic regimens, glycemic control strategies, hemodynamic monitoring thresholds, or limb perfusion optimization) versus usual care. Results are directly relevant to surgeons, hospitalists, and payers because improved perioperative management can reduce length of stay, readmissions, and high-cost complications that drive inpatient reimbursement under this DRG.
Comparative effectiveness research on amputation level and technique: observational cohort studies or randomized trials evaluating functional outcomes, stump healing, reoperation rates, and resource use between different amputation levels (toe vs transmetatarsal vs partial foot; forearm vs more proximal upper limb) and surgical techniques (flap design, bone management, closure methods) in patients with circulatory system-related tissue loss. These studies focus on patients stratified by vascular status, comorbidities such as diabetes and renal disease, and baseline mobility to determine which approaches maximize tissue viability and preserve function while minimizing complications. Findings inform surgeons and payers about which procedures provide the best balance of clinical benefit and cost-effectiveness for specific patient subgroups, influencing DRG-related utilization and post-acute care needs.
Post-discharge outcomes and care coordination studies: prospective cohort studies and intervention trials examining rehabilitation access, prosthetic fitting timelines, wound care follow-up, and secondary prevention (vascular risk modification) on long-term outcomes like mobility, quality of life, recurrent limb events, and readmissions in patients discharged after toe or upper limb amputation for circulatory disease. These investigations enroll patients transitioning from inpatient care to home or skilled nursing, testing care-management models, telehealth wound monitoring, or structured vascular clinics to reduce avoidable readmissions and recurrent ischemic events. Results are critical for payers and health systems because effective post-discharge strategies can lower downstream costs, influence bundled payment performance, and improve metrics that affect DRG reimbursement risk.

OpenPayer

Summary & Overview

Upper Limb and Toe Amputation for Circulatory System Disorders with CC: Inpatient Reimbursement Overview

DRG 256 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes